IBDEI09I ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4014,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4014,1,2,0)
 ;;=2^92630
 ;;^UTILITY(U,$J,358.3,4014,1,3,0)
 ;;=3^Auditory Rehab;Prelingual Hearing Loss
 ;;^UTILITY(U,$J,358.3,4015,0)
 ;;=92633^^13^182^2^^^^1
 ;;^UTILITY(U,$J,358.3,4015,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4015,1,2,0)
 ;;=2^92633
 ;;^UTILITY(U,$J,358.3,4015,1,3,0)
 ;;=3^Auditory Rehab;Postlingual Hearing Loss
 ;;^UTILITY(U,$J,358.3,4016,0)
 ;;=92625^^13^182^5^^^^1
 ;;^UTILITY(U,$J,358.3,4016,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4016,1,2,0)
 ;;=2^92625
 ;;^UTILITY(U,$J,358.3,4016,1,3,0)
 ;;=3^Tinnitus Assessment
 ;;^UTILITY(U,$J,358.3,4017,0)
 ;;=99366^^13^183^1^^^^1
 ;;^UTILITY(U,$J,358.3,4017,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4017,1,2,0)
 ;;=2^99366
 ;;^UTILITY(U,$J,358.3,4017,1,3,0)
 ;;=3^Team Conf w/ Pt by HC Pro,30 Min
 ;;^UTILITY(U,$J,358.3,4018,0)
 ;;=99368^^13^183^2^^^^1
 ;;^UTILITY(U,$J,358.3,4018,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4018,1,2,0)
 ;;=2^99368
 ;;^UTILITY(U,$J,358.3,4018,1,3,0)
 ;;=3^Team Conf w/o Pt by HC Pro,30 Min
 ;;^UTILITY(U,$J,358.3,4019,0)
 ;;=379.31^^14^184^1
 ;;^UTILITY(U,$J,358.3,4019,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4019,1,3,0)
 ;;=3^379.31
 ;;^UTILITY(U,$J,358.3,4019,1,4,0)
 ;;=4^Aphakia without IOL implant
 ;;^UTILITY(U,$J,358.3,4019,2)
 ;;=^9445
 ;;^UTILITY(U,$J,358.3,4020,0)
 ;;=366.9^^14^184^2
 ;;^UTILITY(U,$J,358.3,4020,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4020,1,3,0)
 ;;=3^366.9
 ;;^UTILITY(U,$J,358.3,4020,1,4,0)
 ;;=4^Cataract NOS
 ;;^UTILITY(U,$J,358.3,4020,2)
 ;;=^20266
 ;;^UTILITY(U,$J,358.3,4021,0)
 ;;=371.00^^14^184^4
 ;;^UTILITY(U,$J,358.3,4021,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4021,1,3,0)
 ;;=3^371.00
 ;;^UTILITY(U,$J,358.3,4021,1,4,0)
 ;;=4^Corneal Disease
 ;;^UTILITY(U,$J,358.3,4021,2)
 ;;=^28398
 ;;^UTILITY(U,$J,358.3,4022,0)
 ;;=362.51^^14^184^11
 ;;^UTILITY(U,$J,358.3,4022,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4022,1,3,0)
 ;;=3^362.51
 ;;^UTILITY(U,$J,358.3,4022,1,4,0)
 ;;=4^Macular Degeneration (ARMD), Dry
 ;;^UTILITY(U,$J,358.3,4022,2)
 ;;=^268636
 ;;^UTILITY(U,$J,358.3,4023,0)
 ;;=362.52^^14^184^12
 ;;^UTILITY(U,$J,358.3,4023,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4023,1,3,0)
 ;;=3^362.52
 ;;^UTILITY(U,$J,358.3,4023,1,4,0)
 ;;=4^Macular Degeneration (ARMD), Wet
 ;;^UTILITY(U,$J,358.3,4023,2)
 ;;=^268637
 ;;^UTILITY(U,$J,358.3,4024,0)
 ;;=377.10^^14^184^14
 ;;^UTILITY(U,$J,358.3,4024,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4024,1,3,0)
 ;;=3^377.10
 ;;^UTILITY(U,$J,358.3,4024,1,4,0)
 ;;=4^Optic Atrophy
 ;;^UTILITY(U,$J,358.3,4024,2)
 ;;=^85926
 ;;^UTILITY(U,$J,358.3,4025,0)
 ;;=377.49^^14^184^15
 ;;^UTILITY(U,$J,358.3,4025,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4025,1,3,0)
 ;;=3^377.49
 ;;^UTILITY(U,$J,358.3,4025,1,4,0)
 ;;=4^Optic Nerve
 ;;^UTILITY(U,$J,358.3,4025,2)
 ;;=^269230
 ;;^UTILITY(U,$J,358.3,4026,0)
 ;;=362.74^^14^184^17
 ;;^UTILITY(U,$J,358.3,4026,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4026,1,3,0)
 ;;=3^362.74
 ;;^UTILITY(U,$J,358.3,4026,1,4,0)
 ;;=4^Retinitis Pigmentosa
 ;;^UTILITY(U,$J,358.3,4026,2)
 ;;=^105693
 ;;^UTILITY(U,$J,358.3,4027,0)
 ;;=362.50^^14^184^13
 ;;^UTILITY(U,$J,358.3,4027,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4027,1,3,0)
 ;;=3^362.50
 ;;^UTILITY(U,$J,358.3,4027,1,4,0)
 ;;=4^Macular Degeneration Eye NOS 
 ;;^UTILITY(U,$J,358.3,4027,2)
 ;;=^73072
 ;;^UTILITY(U,$J,358.3,4028,0)
 ;;=438.7^^14^184^10
 ;;^UTILITY(U,$J,358.3,4028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4028,1,3,0)
 ;;=3^438.7
 ;;^UTILITY(U,$J,358.3,4028,1,4,0)
 ;;=4^Lt Effect of Stroke w/Vision prob
 ;;
 ;;$END ROU IBDEI09I
